Advanced search
Publication Cover
Journal of Medical Economics Volume 18, 2015 - Issue 10
Submit an article Journal homepage
632
Views
3
CrossRef citations to date
0
Altmetric
Original article

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus

Vanessa TaiebAmaris, London, UKCorrespondence[email protected]
,
Maud PacouAmaris, Paris, France
,
Sophia HoAmaris, London, UK
,
Ségolène PettréAmaris, London, UK
,
Suzy Van SandenJanssen EMEA, Beerse, Belgium
,
Marta PisiniJanssen EMEA, Beerse, Belgium
,
Andrew UstianowskiNorth Manchester General Hospital, Manchester, UK
&
Angelika MehnertJanssen-Cilag GmbH, Neuss, Germany
 show all
Pages 787-796 | Accepted 28 Apr 2015, Published online: 26 May 2015

Figures & data

Figure 1. PRISMA diagram.

Figure 1. PRISMA diagram.

Figure 2. Global network of evidence, treatment-naïve patients. Note: TxPRy: telaprevir for x weeks in combination with PR for y weeks; BxPRy: boceprevir for x weeks in combination with PR for y weeks; SMVxPRy: simeprevir for x weeks in combination with PR for y weeks; PR response guided therapy noted as 24/48 (simeprevir, telaprevir) or 28/48 (boceprevir).

Figure 2. Global network of evidence, treatment-naïve patients. Note: TxPRy: telaprevir for x weeks in combination with PR for y weeks; BxPRy: boceprevir for x weeks in combination with PR for y weeks; SMVxPRy: simeprevir for x weeks in combination with PR for y weeks; PR response guided therapy noted as 24/48 (simeprevir, telaprevir) or 28/48 (boceprevir).

Figure 3. Results for SVR: OR [95% CrI] and probabilities (Prob) for SMV to perform better than comparators.

Figure 3. Results for SVR: OR [95% CrI] and probabilities (Prob) for SMV to perform better than comparators.

Figure 4. Safety results—OR [95% CrI] and probabilities (Prob) for SMV to perform better than comparators.

Figure 4. Safety results—OR [95% CrI] and probabilities (Prob) for SMV to perform better than comparators.

Figure 5. Global network of evidence, treatment-experienced patients. Note: TxPRy: telaprevir for x weeks in combination with PR for y weeks; BxPRy: boceprevir for x weeks in combination with PR for y weeks; SMVxPRy: simeprevir for x weeks in combination with PR for y weeks; PR response guided therapy noted as 24/48 (simeprevir, telaprevir) or 36/48 (boceprevir).

Figure 5. Global network of evidence, treatment-experienced patients. Note: TxPRy: telaprevir for x weeks in combination with PR for y weeks; BxPRy: boceprevir for x weeks in combination with PR for y weeks; SMVxPRy: simeprevir for x weeks in combination with PR for y weeks; PR response guided therapy noted as 24/48 (simeprevir, telaprevir) or 36/48 (boceprevir).
Supplemental material

Supplemental Material.pdf

Download PDF (98.5 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.